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ABSTRACT
Purpose To investigate the sustained ocular delivery of small
and large drugmolecules from photocrosslinked poly(ethylene
glycol) diacrylate (PEGDA) implants with varying pore
forming agents.
Methods Triamcinolone acetonide and ovalbumin loaded
photocrosslinked PEGDA implants, with or without pore-
forming agents, were fabricated and characterised for chemi-
cal, mechanical, swelling, network parameters, as well as drug
release and biocompatibility. HPLC-based analytical methods
were employed for analysis of two molecules; ELISA was used
to demonstrate bioactivity of ovalbumin.
Results Regardless of PEGDA molecular weight or pore for-
mer composition all implants loaded with triamcinolone
acetonide released significantly faster than those loaded with
ovalbumin. Higher molecular weight PEGDA systems
(700 Da) resulted in faster drug release of triamcinolone
acetonide than their 250 Da counterpart. All ovalbumin re-
leased over the 56-day time period was found to be bioactive.
Increasing PEGDA molecular weight resulted in increased
system swelling, decreased crosslink density (Ve), increased
polymer-water interaction parameter (χ), increased average
molecular weight between crosslinks (Mc) and increased mesh
size (ε). SEM studies showed the porosity of implants increased
with increasing PEGDA molecular weight. Biocompatibility
showed both PEGDA molecular weight implants were non-
toxic when exposed to retinal epithelial cells over a 7-day
period.
Conclusion Photocrosslinked PEGDA implant based systems
are capable of controlled drug release of both small and large
drug molecules through adaptations in the polymer system
network. We are currently continuing evaluation of these sys-
tems as potential sustained drug delivery devices.
KEY WORDS ocular drug delivery . photocrosslinked .
poly(ethylene glycol) diacrylate . protein delivery . triamcinolone
acetonide
ABBREVIATIONS
AMD Age-related macular degeneration
Da Daltons
DME Diabetic macular edema
DR Diabetic retinopathy
HPLC High performance liquid chromatography
MTS (3-(4,5-dimethylthiazol-2-yl)-
5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2Htetrazolium)
MW Molecular weight
OVA ovalbumin
PBS Phosphate buffered saline
PEGDA poly(ethylene glycol) diacrylate
SEC Size exclusion chromatography
SEM Scanning electron microscope
TA triamcinolone acetonide
UV ultraviolet
VEGF Vascular endothelial growth factor
INTRODUCTION
Delivery of drug molecules to treat visually impairing ocular
diseases, namely those that originate in the posterior segment
of the eye, has been an extremely challenging task for phar-
maceutical scientists and retinal specialists. The most
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prevalent posterior segment ocular conditions that affect vi-
sion are age-related macular degeneration (AMD) and diabet-
ic retinopathy (DR). AMD results in damage to the macula,
the central area of the retina, a zone that is essential for de-
tailed and central vision. The condition is extremely detrimen-
tal to those affected as it results in the inability to carry out
normal, everyday activities due to the disruption of central
vision. AMD is the leading cause of irreversible blindness in
the Western world (1–4), estimates show 8.7% of the global
population are suffers (5) and the World Health Organisation
state that 8 million people have severe blindness due to AMD
(6). The development of DR is common in poorly controlled
diabetic patients. Over time consistently raised blood glucose
levels can cause narrowing and leaking of blood vessels within
the posterior segment of the eye. This results in retinal damage
and ultimately blindness if the condition is left untreated.
There is estimated to be 93 million patients suffering with
DR worldwide (7).
The treatment of both AMD and DR involves the delivery
of large molecular weight (MW) protein based therapeutics
(e.g. anti-vascular endothelial growth factors (VEGF)), which
aims to prevent the choroidal neovascularisation (CNV) asso-
ciated with these conditions. In addition, small MW cortico-
steroid molecules are also used to reduce the inflammation
associated with AMD and DR, and theoretically they can also
benefit patients by acting as anti-angiogenic and anti-fibrotic
agents and stabilising the blood retinal barrier (8). Delivery of
these agents to the required site of action is problematic, as the
eye contains multiple barriers designed for protection and to
aid in preventing unwanted substances entering the ocular
tissue. This results in many challenges associated with the de-
livery of both small and larger MW drug molecules into the
eye and profusion to the intended area of action.
The posterior segment cannot be treated effectively using
topical formulations, as they are incapable of reaching the
required site of action. Consequently intravitreal injections
have become the standard delivery method, but due to their
invasive nature multiple adverse effects are associated (9). The
limitations of current delivery methods have led to increased
research into controlled release systems for ocular delivery. A
significant emerging field of research is implantable polymer
based systems, which aim to provide sustained release of drug
molecules in the back of the eye. There are three polymer
based ocular implants currently on the market; Retisert®
and Iluvein® are non-biodegradable systems that provided
sustained delivery of fluocinolone acetonide for up to 3 years
(10). The only biodegradable system available is Ozurdex®
that releases dexamethasone over a 6 month time period (10).
At present no ocular controlled release system has demon-
strated the ability to adequately deliver peptide or protein
molecules to the posterior segment. This is a major problem
as multiple therapies indicated to treat posterior segment dis-
orders involve the use of protein-based molecules.
Photocrosslinked implant systems have been exploited for
multiple applications over the past decades. Their use in bio-
medical applications such as tissue engineering (11,12) and
prevention of thrombosis (13,14) is well documented. In terms
of use in drug delivery (15,16) these photocrosslinked systems
have shown the ability to provide drug release for markedly
extended time periods.
Poly(ethylene glycol) (PEG) based polymers are used in a
variety of biomedical applications as they can be easily syn-
thesised and exhibit good biocompatibility and tissue-like
properties (17). Specifically, PEG based polymers containing
acrylate side groups show great potential in the area of
photocrosslinking. PEG diacrylate (PEGDA) contains
double-bond acrylate groups at each end of the PEG chain,
giving it the ability to undergo free radical photo-
polymerisation in the presence of a photoinitiator molecule
(18) to produce a photocrosslinked system or implant (11).
PEGDA is non-toxic, elicits only a minimal immune response
(19,20) and is a biodegradable polymer. Browning et al. recent-
ly demonstrated that the primary mechanism of PEGDA hy-
drogel degradation in vivo is due to hydrolysis of the end group
acrylate esters linkages within the polymer (21). PEGDA is
available in various MWs making it ideal for obtaining the
required system crosslink density (18) and its highly versatile
nature allows for small adaptions to optimise the system (21).
As PEGDA has been proven to be a favorable material for
biological applications (25) and is used in the engineering of a
number of tissues such as bone (26), cartilage (27) and cornea
(28,29), in this study we investigate photocrosslinked PEGDA
hydrogels for their use in drug delivery systems. The tunable
nature of photocrosslinked PEGDA hydrogels systems and
their accepted use in biomedical applications makes them ide-
al candidates for adaption to provide a controlled drug re-
lease. Specifically, photocrosslinked systems, such as those
composed of PEGDA, have advantages in the release of pro-
tein drug molecules. Most significantly initiation of
photocrosslinkage does not require extreme pH conditions,
organic solvents or high temperature (30), which could cause
issues when working with protein molecules.
This study aims to fabricate and characterise PEGDA-
based photocrosslinked implants of different polymer MW
(250 and 700 Da) for sustained ocular delivery of triamcino-
lone acetonide (TA, 434 Da) and ovalbumin (OVA, 45 kDa).
Alternations in the MW of PEGDA results in changes to the
crosslink density of the system formed, with lower MWs
resulting in a more densely crosslinked system. This study
has selected PEGDA at MW 250 and 700 Da for investigate
to assess the degree of difference in release profile and implant
properties at these MWs. With regards to drug molecule se-
lection, TA has been chosen for its clinical relevance in
treating AMD and DR, while OVA was chosen as a model
protein molecule that is similar in MW to anti-VEGF drug
ranibizumab (Lucentis®). In vitro release profiles from the
 36 Page 2 of 17 Pharm Res  (2018) 35:36 
PEGDA implants were investigated. Due to the vast difference
in MW of each drug, a number of pore forming agents have
been incorporated into the PEGDA implants to assess their
effect on pore formation, drug release, protein bio-stability,
mechanical properties, swelling behaviour, network parame-
ters and biocompatibility.
Materials
PEGDA with MW of 250 Da and 700 Da (hereafter re-
ferred as PEGDA 250 and PEGDA 700), 1-[4-(2-
hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propanone
(Irgacure® 2959), OVA, mannitol, sodium bicarbonate,
sodium carbonate, gelatin, maltose, sucrose, sodium chlo-
ride, monoclonal anti-chicken egg albumin produced in
mouse, tetramethylbenzidine liquid (TMB) substrate, hy-
drochloric acid and HPLC grade acetonitrile were pur-
chased from Sigma-Aldrich (Basingstoke, England). TA
was purchased from Spruyt Hil len bv (Ijsselstein,
The Netherlands). Scotch™ Magic tape was purchased
from 3 M, Berkshire UK. Phosphate buffered saline
(PBS), HPLC grade water and all other chemicals used
were of analytical grade. 27G needles were purchased from
Terumo UK Ltd. (Surrey, United Kingdom). 1 mL dispos-
able medical syringes purchased from Becton, Dickinson
and Company (Oxford, UK). Rabbit anti-OVA-biotin con-
jugate (polyclonal) was purchased from Novus Biologicals
(Cambridge, United Kingdom). Streptavidin-Horse radish
peroxidase conjugate was purchased from BioLegend®
(San Diego, United States). Superblock T20 buffer was pur-
chased from Thermo Scientific Pierce (Rockford, United
Sta te s ) . DAPI (4 ′ , 6 -Diamid ino-2 -Pheny l indo le ,
D i h yd r o ch l o r i d e ) s o l u t i o n ( F i s h e r S c i e n t i f i c ,
Loughborough, UK).
METHODS
Fabrication of PEGDA Implants
The drugs under investigation (TA and OVA) were incorpo-
rated in PEGDA (700 or 250) to produce 2.5%w/w solutions.
Once the drug was fully dissolved/suspended the desired
amount o f pore former was then added to the
drug/PEGDA (700 or 250) solutions and left to dissolve at
room temperature. Prior to photocrosslinking, Irgacure®
2959 (2% w/v in 70% ethanol in water) was added to the
formulation and vortexed for 1 min to ensure complete
mixing. The composition of all prepared formulations are
shown below in Table I.
Moulds for implant fabrication were then prepared using
Scotch™ Magic tape (one strip has a thickness of 50 μm)
layered onto glass microscope slides and cut to the required
implant dimensions of 10 × 5 × 0.5 mm (Fig. 1). The previ-
ously prepared formulations (Table I) where then loaded
into the moulds using a 27G needle. Each mould was passed
through the UV crosslinker, Fusion UV Light-Hammer 6
high power UV curing system (Maryland, USA) fitted with
a BD^ class mercury discharge bulb, with a belt speed of 10–
10.5 m/s and at wavelength 365 nm, lamp intensity 50%
and 5 times to crosslink the formulation. Each implant was
then carefully removed from their mould and weighed.
In vitro Drug Release Studies
For in vitro drug release studies, TA loaded implants were
placed in a plastic tub containing 50 mL PBS (pH 7.4 ± 0.2)
release media to maintain sink conditions. All the experiments
were carried out in triplicate. The tubs were then incubated at
37°C and 40 RPM and at predetermined time intervals the
entire mediumwas removed and replaced with fresh medium.
The concentration of released TA in the PBS samples was
then analysed using the HPLC assay described below.
For in vitro drug release study of OVA each preformed im-
plant was placed in a glass vial containing 5 mL PBS (pH 7.4 ±
0.2) release media and samples as above. The concentration of
released OVA in the PBS samples was then analysed using the
size-exclusion HPLC assay described below.
Analytical Techniques
Analysis of TA samples was carried out using reversed-phase
Agilent 1260 Infinity Quaternary System HPLC using an
Agilent Zorbax Eclipse Plus 250 mm, 4.6 mm ID, 5 μm par-
ticle size, C18 bonded silica column and an Agilent Zorbax
guard column held at 25°C (Agilent Technologies Ltd.,
Stockport, UK). A mobile phase of 60% water and 40% ace-
tonitrile at UV absorbance of 236 nm was found to give op-
timal peak shape. Injection volume was fixed to 20 μl and flow
rate was set at 0.8 mL/min. A standard calibration curve was
then prepared, between the concentration range of 0.1–
250 μg/mL, and used to determine the TA drug concentra-
tion in each of the release samples.
Analysis of OVA samples was carried out using Agilent
1260 Inf inity Quaternary System HPLC using a
Phenomenex BIOSEP-SEC-s3000 300 mm, 7.8 mm ID,
3 μm particle size column and GFC 3000 guard column held
at 25°C (Phenomenex., Cheshire, UK). A mobile phase of
250 mM NaCl at UV absorbance of 214 nm was found to
give optimal peak shape. Injection volume was fixed to 20 μL
and flow rate was set at 1 mL/min. A standard calibration
curve was then prepared, between the concentration range
3.125–100 μg/ml, and used to determine the OVA drug con-
centration in each of the release samples.
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ELISA for Bioactivity Analysis of OVA
The bioactivity of released OVA was determined using a sand-
wich ELISA technique previously developed by McCrudden
et al. (31). Monoclonal anti-chicken egg ovalbumin antibody
produced in mouse (MoAb) was diluted in 0.1 M bicarbonate
buffer, pH 9.6 to the optimised concentration of 2.5 μg/mL.
An aliquot (100 μl) of this anti-ovalbumin was dispensed into
the plate and incubated overnight at 4°C. The plate washed to
remove unbound antibody (0.05% Tween 20 in PBS) 3 times.
Blocking was performed with SuperBlock® T20 (200 μl/well),
for 2 h. A 50 μl volume of sample was dispensed into each well,
with each sample analysed in triplicate and a freshly prepared
standard concentration curve was plated (50–1000 ng/ml), and
incubated for 1 h. Excess sample was washed off (as before).
Following this, 50 μl of rabbit anti-chicken egg ovalbumin,
polyclonal antibody conjugate with biotin at the optimised con-
centration of 1 μg/mL in SuperBlock® T20 buffer was added
to each well for 1 h. Excess sample was washed off (as previously
detailed). The plate was then incubated with Streptavidin –
Horseradish Peroxidase (Strep-HRP) conjugate at the
optimised dilution of 1:2000 in PBS, for 30 min. Washing
was performed as before. To detect the antibody binding,
100 μl of substrate TMB (3,3′,5,5′-tetramethylbenzidine) was
added to each well and incubated for 20 min and the reaction
was ended using 100 μl/well, 4.0 M hydrochloric acid. Optical
density was measured at 450 nm using a micro 96 well plate
spectrophotometer (Powerwave™ XS, Bio-Tek Instruments
Inc., Minooski, USA). Results were expressed as means ± SD
of three replicates.
Dynamic and Equilibrium Swelling Studies
For swelling studies the crosslinked implants were weighed as
mo (xerogels) and were then swollen in HPLC grade water for
48 h at 37°C. At regular intervals, the implants were removed,
blotted with filter paper to eliminate excess surface water and
weighed as mt (hydrogels). The implants at equilibrium were
weighed as me, and were dried under vacuum at 80°C for 24 h
to obtain extracted xerogels, which were weighed as md (32).
The percentage swelling, % S, and equilibrium water content,
EWC, was calculated, respectively, by using Eq. 1 and 2.
%Swelling ¼ Mr−Mo
Mo
 
x 100 ð1Þ
Table I Composition of PEGDA 700 and PEGDA 250 Photocrosslinked
Implants
Formulation
code
Drug loaded at
2.5% w/w
Pore former
loaded at 10% w/w
PEGDAMW
T1 TA – 700
T2 TA – 250
T3 TA Mannitol 700
T4 TA Mannitol 250
T5 TA NaHCO3 700
T6 TA NaHCO3 250
T7 TA NaCO3 700
T8 TA NaCO3 250
T9 TA Gelatin 700
T10 TA Gelatin 250
T11 TA Maltose 700
T12 TA Maltose 250
T13 TA Sucrose 700
T14 TA Sucrose 250
T15 TA NaCl 700
T16 TA NaCl 250
O1 OVA – 700
O2 OVA – 250
O3 OVA Mannitol 700
O4 OVA Mannitol 250
O5 OVA NaHCO3 700
O6 OVA NaHCO3 250
O7 OVA NaCO3 700
O8 OVA NaCO3 250
O9 OVA Gelatin 700
O10 OVA Gelatin 250
O11 OVA Maltose 700
O12 OVA Maltose 250
O13 OVA Sucrose 700
O14 OVA Sucrose 250
O15 OVA NaCl 700
O16 OVA NaCl 250
C1 – – 700
C2 – – 250
C3 – Mannitol 700
C4 – Mannitol 250
C5 – NaHCO3 700
C6 – NaHCO3 250
C7 – NaCO3 700
C8 – NaCO3 250
C9 – Gelatin 700
C10 – Gelatin 250
C11 – Maltose 700
C12 – Maltose 250
C13 – Sucrose 700
C14 – Sucrose 250
C15 – NaCl 700
Table I (continued)
Formulation
code
Drug loaded at
2.5% w/w
Pore former
loaded at 10% w/w
PEGDAMW
C16 – NaCl 250
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%EWC ¼ Mo−Md
Md
 
x 100 ð2Þ
Network Parameters
Mc, the average MW between crosslinks, is calculated using
Flory-Rehner theory, which gives the values of Mc between
two adjacent crosslinks and represents the degree of
crosslinking of hydrogel networks (33) and is shown in Eq. 3.
The magnitude of Mc affects the mechanical, physical and
thermal properties of crosslinked polymers, as we descried
previously (32).
Mc ¼ −dpV s∅
1=3
ln 1−∅ð Þ þ∅þ χ ∅2  ð3Þ
Vs is the molar volume of water (18 cm
3/mol), Φ is volume
fraction of polymer in the hydrogel, χ is the Flory–Huggins
polymer–solvent interaction parameter.
The volume fraction of a polymer, Φ, in the swollen state
defines the amount of liquid that can be enter a hydrogel and
is described as a ratio of the polymer volume to the swollen gel
volume (32), show in Eq. 4.
∅ ¼ 1þ dp
ds
ma
mb
 
−1
 −1
ð4Þ
Where, ma and mb are the mass of polymer before and
after swelling and dp and ds are the densities of polymer and
solvent, respectively. The density of the polymeric films was
calculated using the following formula; dp = w/SX, where; X
is the average thickness of the film, S is the cross-sectional area
and w weight of the film (34).
The polymer–water interaction parameter (χ) of hydrogels
can be obtained experimentally via Eq. 5.
χ ¼ 1
2
þ ∅
3
ð5Þ
Crosslink density, Ve, was determined using Eq. 6. Ve
represents the number of elastically effective chains, totally
induced in a perfect network, per unit volume (32). Where
NA is Avagadro’s number (6.023 × 10
23 mol−1) (32).
V e ¼ dpN A=Mc ð6Þ
Mesh size was calculated first by assessing the distance be-
tween polymer chains, r0
−2. Where l is the average bond
length, 1.54, Cn is the characteristic ratio for the polymer here
we will use the Cn of PEG, typically 4.0 (35,36).
ro
−2 	12 ¼ l nð Þ12 Cn 12 ð7Þ
The mesh size, ε, was then calculated by:
ε ¼ ∅13 ro−2
 	−12 ð8Þ
Mechanical Strength
Addition of pore forming agents on the implant mechanical
property was assessed via the comparison of implant strength
and integrity. This was conducted using a TA.XTplus
Photocrosslinked implant
removed from mould Implant mouldPhoto-crosslinking of implants
Loading of gel 
Formulation in the mould
Glass slide Layered with ScotchTM 
Magic tape  
Tape cut to provide implant mould 
(10 x 5 x 0.5 mm) 
UV Light
Fig. 1 Schematic representation
demonstrating PEGDA implant
fabrication.
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Texture Analyser (StableMicro Systems, Surrey, UK) to com-
press the implants 5 mm, as shown in Fig. 2. The implants
were tested directly after fabrication (dry implants) and then
again after 24 h in PBS (pH 7.3 ± 0.2) (wet implants). Implants
were attached to the probe and the Texture Analyser was set
in compression mode, and the probe moved towards a solid
aluminium block. When the implant came in contact with the
solid surface, the test began with the probe moving at
0.05 mm/s. The maximum force required to compress the
implant to 5 mm was recorded using the Exponent TA.XT
software (Version 4). The study was performed in triplicate for
each formulation.
Structural Analysis using Scanning ElectronMicroscope
(SEM)
In order to investigate the structural differences in implants
composed of varying PEGDA molecular weights and assess
the addition of pore forming agents, SEM images were col-
lected using a Hitachi TM 3030 Table top Microscope
(Hitachi High-Technologies Europe GmbH, Krefeld
Germany). After photocrosslinking and placement in PBS
(pH 7.3 ± 0.2) for both 24 h and 7 days the implants were
then removed and rinsed using deionised water, with the ex-
cess liquid removed using tissue paper, the implants were left
to dry. Once dry, the implants were sectioned accordingly and
mounted for imaging.
Biocompatibility Testing
Biocompatibility experiments were carried out by both indi-
rect and direct contact methods. During formulation prepa-
ration both PEGDA 700 and PEGDA 250 were filtered
through a sterile 0.2 μm syringe filter with a membrane ma-
terial of cellulose acetate (VWR®, International Ltd.,
Leicestershire, UK). Prepared formulations where then load-
ed into the moulds and crosslinked using a UV crosslinker,
Fusion UV LightHammer 6 high power UV curing system
(Maryland, USA) fitted with a BD^ class mercury discharge
bulb, with a belt speed of 9.8-10 m/s and at wavelength
365 nm, lamp intensity 50% and 5 times to crosslink the
formulation.
Indirect Contact Assay
Each implant was then carefully removed from their mould,
dipped in ethanol to sterilise and placed into 5 mLDMEM/F-
12 media (Gibco®, Life Technologies™, Paisley UK) in
autoclaved glass vials. At defined time points (1, 4 and 7 days
after formation), the entire 5 mL of media was removed and
replaced with fresh media. The media collected at various
time points was then exposed to the cells. All treatments were
performed on human retinal pigment epithelia cells (ARPE-
19) seeded in 96-well plates (Nunc®, Denmark) at a cellular
density of 2 × 104 cells/well, which were incubated at 37°C
for 24 h in DMEM/F-12. The DMEM/F-12 medium was
removed and replaced with 200 μl of the release media from
each time point (fresh media was used as the control).
Subsequently, the cells were incubated for a further 24 h.
Direct Contact Assay
Each implant was removed from their mould, cut to size,
dipped in ethanol to sterilise and placed into 5 mL
DMEM/F-12 media (Gibco®, Life Technologies™, Paisley
UK) in autoclaved glass vials and incubated at 37°C until
swollen to equilibrium. Simultaneously, ARPE-19 cells were
seeded in 96-well plates (Nunc®, Denmark) at a cellular den-
sity of 2 × 104 cells/well and incubated at 37°C for 24 h in
DMEM/F-12. Media was then removed from each well and
implants were carefully placed on top of the cells, followed by
addition of 200 μl of fresh media. The cells were then incu-
bated for a further 24 h. Following aspiration of the remaining
media, the 96-well plate was inverted to allow removal of each
implant from the treatment wells.
For both indirect and direct contact methods cell viability
was then determined using a MTS assay and DAPI (4′,6-
diamidino-2-phenylindole) fluorescent staining.
For the cell proliferation assay 20 μl of Promega G3580
MTS assay solution (Promega Corporation, Wisconsin, USA)
was added to each well. After 2 h of incubation, the UV
absorbance was determined at 490 nm. The percentage cell
viability was then calculated by dividing the average absor-
bance value of each formulation by the average absorbance of
the control (which consisted of ARPE-19 cells grown inmedia,
Fig. 2 Illustration of texture analyser set up from implant compression.
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without any exposure to PEGDA implants) and multiplying
by 100.
For DAPI fluorescent staining 50 μl of Formalin was used
to fix the cells before the addition of 50 μl DAPI solution
(Fisher Scientific, Loughborough, UK) diluted 2:10,000 in
PBS, which was subsequently aspirated from the cells after
10 min and replaced with 50 μl of PBS, the cells were then
imaged using a fluorescent microscope under the DAPI filter.
Statistical Analysis
The effects of PEGDA MW and the loading of various pore
forming agents on swelling, mechanical strength, cell viability
and drug release from the implant formulations were analysed
using a one-way analysis of variance (ANOVA) where
p< 0.05 was taken to represent a statistically significant differ-
ence. When there was a statistically significant difference,
post-hoc Tukey’s HSD tests were used. Statistical analysis
was conducted using GraphPad Prism Version 6 (GraphPad
Software Inc., San Diego, USA).
RESULTS
In vitro Drug Release
TA release, from all PEGDA 700 implant formulations,
reached approximately 100% between days 21–28. From
the range of pore forming agents selected only sodium bicar-
bonate (T7) and sucrose (T13) display a slower release rate
than the control formulation (T1) without pore forming agent,
and this observed difference is not significant (p= 0.9971 and
0.8759 respectively). All other formulation types released TA
faster than the control. However, there was not a significantly
faster rate of release, with the exception of gelatin (T9).
Gelatin provides a significant increase in the day 1 release
(burst release) of TA, 24.82% release was exhibited compared
to 13.70% from the control (p= 0.0437), but following this
time point release did not remain significantly greater than
the control (Fig. 3a).
With regards to TA release from PEGDA 250 implants
(Fig. 3b); no pore-forming agent showed significantly greater
release than the control formulation (T2) before the day 252
time point is reached. At day 252 loading with sodium bicar-
bonate (T6) resulted in the greatest drug release, 53.51%,
followed by maltose (T12) at 51.69% and then sodium car-
bonate (T8) at 38.45%, compared to the control formulation
(T2), which released 25.61% of the drug loading. Of these
three pore forming agents, the release from sodium bicarbon-
ate (T6) and maltose (T12) exhibited a statistically significant
increase in release rate when compared to the control formu-
lation (p= 0.0450 and 0.0465 respectively). Regardless of the
pore-forming agent loaded, PEGDA 250 implants showed a
significantly slower release rate than those prepared with
PEGDA 700.
OVA release from all implants, regardless of PEGDAMW
or pore forming loading, follow a similar release pattern. An
initial burst release of drug is observed, within the first 24 h,
followed by a reduction in release in the following days.
Results highlight that the effect of PEGDA MW on release
of OVA is less substantial than the effect of pore former load-
ing. Only formulations loaded with sodium carbonate (O7
and O8), sodium bicarbonate (O5 and O6), gelatin (O9 and
O10) and sucrose (O13 and O14) showed a significant differ-
ence in release across the two PEGDAMW’s. Conversely, the
addition of pore forming agent has a significant effect onOVA
release in almost all formulation types. Regardless of PEGDA
MW the three pore forming agents that cause the most signif-
icant increase in OVA release over the 84-day period were
sodium carbonate (O7 and O8, releasing 62.34% and
38.59% respectively), sodium bicarbonate (O5 and O6, re-
leasing 35.79% and 46.42% respectively) and sucrose (O13
and O14, releasing 30.85% and 41.48% respectively).
Interestingly, both PEGDA 700 and PEGDA 250 implants
loaded with mannitol (O3 and O4) and maltose (O11 and
O12) release significantly less OVA than the control formula-
tion (at day 1, p< 0.0001 and p= 0.0005 respectively, at day
84, p< 0.0001 and p= 0.0018 respectively).
With respect to PEGDA 700 implants sodium carbonate
(O7) shows the most significant increase in OVA release (at
day 1 39.95% released) when compared to control (at day 1
14.68% released) (p< 0.0001), followed by sodium bicarbon-
ate (O5) (at day 1 26.40% released) (p< 0.0001) and then
sucrose (O13) (at day 1 release 23.41% released)
(p< 0.0011). The increase in OVA release with these three
pore forming agents remains significant at day 84, with the
control implant exhibiting 22.23% release compared to
62.34% from sodium carbonate (O7) (p< 0.0001), 35.79%
from sodium bicarbonate (O5) (p< 0.0001) and 30.85% from
sucrose (O13) (p< 0.0524).
From OVA loaded PEGDA 250 implants, with the excep-
tion of mannitol (O4) and maltose (O12), all remaining pore
forming agents release significantly more than the control
samples, across all times points (day 1 p< 0.0001 for sodium
carbonate, sodium bicarbonate, getalin and sucrose. At day
84, p< 0.0001 for sodium carbonate, sodium bicarbonate,
getalin and p= 0.0022 for sucrose).
Bioactivity of OVA
From HPLC chromatograms it can be confirmed that only
visible peaks present are attributed to OVA and the dimer
molecule, no degradation products are visible eluting from
the column, indicating that OVA remains stable through the
study (Fig. 5). However, this observation requires confirmation
and thus OVA bioactivity was tested to ensure the tertiary
Pharm Res  (2018) 35:36 Page 7 of 17  36 
structure was maintained throughout the release study. Release
samples from the implants were studied to determine whether
the releasedOVAwas still active and that the quantity of OVA
detected from the SEC HPLC assay was structurally sound.
Table II presents data relating to the percentage of active
OVA released after 56 days. Results indicate that active
OVA was released from the implants throughout the time pe-
riod. From day 1–56, greater than 90% of the OVA released
was determined to be active for all formulation types. The
presence or absence of pore forming agents does not appear
to play a significant role inOVA activity within PEGDA 700 or
PEGDA 250 implant systems. (Figures 6 and 7)
Swelling Studies
In relation to implant swelling, varying the PEGDAMW shows
significant differences within the implant. PEGDA 700 implants
exhibit 35–50% swelling across all formulations; in contrast no
PEGDA 250 implant swells above 5%. In fact C6 (containing
sodium bicarbonate) exhibited an initial drop in implant weight,
whichmay be due to loss of uncrosslinked surfacemonomer, but
this weight drop is not significant (p= 0.9537).
When directly comparing formulations containing the
same pore forming agents but different MW’s of PEGDA,
the difference in system swelling was highly significant. With
the head to head comparison of each pore forming agent with
their differing MW counterpart p < 0.0001 for all pore
forming agents and control formulations.
With regards to swelling of PEGDA 700 implants the only
pore forming agents that made a significant difference to
swelling is gelatin (C9) (p= 0.0254). No pore forming agent
loaded in PEGDA 250 implants shows a significant difference
in swelling when compared to the control formulation.
Network Parameters
As shown in Table III, pore former loading does not play a
significant role in the systems network parameters. However,
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the crosslink density, Ve, increases notably with a decrease in
PEGDA MW within the implants. The network parameters
also assess the polymer-water interaction within the system. In
polymer–water systems, the higher the value of χ, the weaker
is the interaction between polymer and water (32). This study
shows that there is a slight increase in the polymer–water
interaction parameter (χ) with increased crosslink density
and decrease in PEGDA MW.
With regards to Mc and mesh size, both values increase as
the MW of PEGDA within the system increases. PEGDA 700
systems have a higher average MW between crosslinks and a
larger mesh size.
Mechanical Strength
Implant mechanical strength was assessed on both dry and
wetted implants (which were exposed to an aqueous environ-
ment for 24 h). All dry implant formulation types loaded with
pore forming agents exhibited an increased mechanical
strength when compared to the control implants (C1 and
C2), containing no pore former loading. The increase in me-
chanical strength observed in the PEGDA 700 implants, was
not statistically significant (p = 0.8746). Conversely, all
PEGDA 250 implants loaded with pore forming agents were
significantly stronger than the control (C2) formulation with
the exception of sodium bicarbonate (C8) When comparing
C2 and C8 p= 0.8964.
SEM Images
SEM images are useful in assessing both the top and cross-
sectional view of implants in intricate detail. Figure 8 high-
lights the smooth external and internal surfaces of control
implants, containing no pore-forming agent (C1 andC2) com-
pared to implants loaded with sodium carbonate (formula-
tions C7 and C8). The PEGDA 700 implants are noticeably
more porous than the lower MW PEGDA implants in the top
sectional image. However, upon analysis of the cross-sectional
images both PEGDA MW implants show significant pore
formation.
With regards to drug loading on implant pore formation,
Fig. 9 highlights the difference between non-drug loaded; TA
loaded and OVA loaded PEGDA 700 and PEGDA 250 im-
plants. As demonstrated in Fig. 8, the PEGDA 700 implants
are noticeably more porous than their PEGDA 250 counter-
part. Additionally, a slight affect on drug loaded can be ob-
served, with non-drug loaded implants (C3 andD3) appearing
more porous than those loaded with TA and OVA.
Biocompatibility
Cell toxicity studies were carried out using ARPE-19 cells to
assess potential cytotoxicity. Experiments were carried out
using both indirect and direct contact assays. Indirect contact
tests involved calculating the percentage cell viability after
ARPE-19 cells were exposed to release media collected 1, 4
and 7 days after the implant was added to the media. Direct
contact tests involved direct placement of the implant on top
of the cell line and assessing the cell viability.
Table II Percentage of active OVA in Release Samples Determined by
ELISA at Selected Time Points (Mean± S.D., n = 3)
Formulation code Percentage of active OVA from release samples
Day 1 Day 28 Day 56
O1 95.44± 3.20 99.53± 0.80 95.65± 3.18
O2 96.09± 5.24 99.47± 5.44 91.46± 6.72
O3 94.77± 4.77 99.65± 5.45 91.21± 7.57
O4 97.97± 6.86 99.17± 6.33 96.05± 3.78
O5 98.97± 6.87 94.53± 8.24 94.42± 6.97
O6 93.06± 3.07 94.70± 2.57 95.28± 14.28
O7 96.49± 0.75 94.94± 2.56 91.57± 8.33
O8 93.99± 1.71 95.53± 1.59 91.65± 1.65
O9 94.04± 4.18 100.01± 5.20 90.09± 4.44
O10 94.61± 4.18 98.86± 1.95 96.56± 0.61
O11 95.26± 0.92 96.61± 3.08 90.44± 2.87
O12 94.72± 2.98 94.09± 1.54 92.76± 6.15
O13 95.06± 4.64 96.86± 1.45 98.38± 2.29
O14 98.66± 5.71 97.39± 2.31 92.06± 3.78
O15 99.97± 3.18 98.11± 4.27 99.98± 5.58
O16 99.64± 5.87 94.57± 4.66 90.05± 3.34
Table III Network Parameters of PEGDA 700 and 250 Formulations
Loaded with 10% w/w of Varying Pore Forming Agents
Formulation code Network Parameters
Ve X 1022 χ Mc ε
C1 4.58 0.82 1.72 0.22
C2 19.91 0.83 0.40 0.17
C3 4.58 0.82 1.79 0.23
C4 17.44 0.83 0.49 0.19
C5 4.43 0.82 1.89 0.23
C6 19.56 0.83 0.47 0.19
C7 3.98 0.81 2.45 0.26
C8 14.60 0.83 0.63 0.19
C9 4.22 0.81 1.93 0.23
C10 16.54 0.83 0.63 0.18
C11 4.27 0.82 2.05 0.24
C12 12.25 0.83 0.59 0.21
C13 4.99 0.82 1.36 0.19
C14 20.42 0.83 0.42 0.18
C15 4.57 0.82 1.85 0.23
C16 12.26 0.83 0.88 0.17
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Percentage cell viability was calculated using anMTS assay
and reading the UV absorbance. In all cases percentage cell
viability was recorded as greater than 80%. Indirect exposure
to these release samples for all PEGDA 700 time points and
for PEGDA 250 at day 4 and 7 actually resulted in cell pro-
liferation as indicated by a percentage cell viability of greater
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than 100% (Fig. 10). Direct contact resulted in greater than
90% cell viability in all cases (Fig. 11).
Cells were also stained with DAPI, which allows the live
cells to be visualised under a fluorescence filter, with live cells
appearing blue. Figure 12 shows the results from staining post
(A) indirect contact assay and (B) direct contact assay, both
images show a high portion of live cells present with morphol-
ogy of the cells maintained, corroborating the cell viability
results.
DISCUSSION
Prevalence of debilitation, sight treating ocular diseases is in-
creasing and although currently there are drug molecules
available to treat these conditions, delivery of these molecules
to the required site of action is suboptimal and associated with
a high level of adverse effects. Therefore, a delivery device
capable of providing an extended time period for drug release
could present a viable alternative to the currently used
intravitreal injections. This study focuses on the development
of novel photocrosslinked biodegradable ocular implants that
will provide continuous sustained drug delivery to the poste-
rior segment of the eye. Photocrosslinked implants composed
of varying PEGDAMWs (250 Da and 700 Da), photoinitiator
and loaded with both small and large MW drug molecules
and various pore forming agents have been formulated and
characterised.
As expected, drug release results differed based on implant
formulation type and was dependent on the type of drug,
PEGDA MW and the pore forming agent. It was postulated
that the addition of water-soluble agents would result in the
formation of pores by dissolving when infiltrated by the aque-
ous release medium, thus causing the porogen to leach out of
the implant system, in turn leaving behind a porous structure
(37). This hypothesis reflected the results observed regarding
OVA from PEGDA implants, with the use of specific pore
forming agents showing marked increase in OVA release
compared to the control formulation (Fig. 4). Namely, sodium
carbonate (O7 and O8), sodium bicarbonate (O5 and O6)
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and sucrose (O13 and O14), were shown to be the most effec-
tive pore forming agents with respect to increasing OVA re-
lease. As stated in the results section, there were only two pore
forming agents that did not improve OVA release, namely
mannitol (O3 and O4) and maltose (O11 and O12), which
both release significantly less OVA than the control formula-
tion. These results indicate that there is a potential interaction
between these pore forming agents and the protein molecule,
which is preventing drug release (38). The effect of pore
forming agent on TA release from PEGDA 700 implants ap-
pears minimal and this is likely related to the MW of the drug
molecule. Due to TAs low MW the introduction of pores
within the system does not produce any significant effect on
release from the implant, as it already exhibits a significant
level of release devoid of pore forming agents. Regarding TA
loaded PEGDA 250 implants, the effect of pore former
loading on drug release does become evident, but not until
long-term release periods are reached.
With respect polymer MW on release rate, there is signif-
icantly higher release of TA from PEGDA 700 implants when
compared to PEGDA 250 implants (p< 0.0001 for all pore
forming agents). This is likely due the lower PEGDA MW
resulting in a denser and more tightly crosslinked system
inhibiting drug release and leaving the TA molecule trapped
within the implant system. In contrast, the effect of PEGDA
MW on drug release is less significant than the use of certain
pore forming agents on OVA release.
It is important to confirm that incomplete OVA release
cannot be attributed to protein denaturation, thus an ELISA
technique was used to determine OVA activity as an alterna-
tive to SEC HPLC for protein detection and quantification.
SEC HPLC chromatogram shown in Fig. 5 suggests active,
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non-degraded OVA was released throughout the study, as
there was the absence of additional or degradation peaks on
the chromatogram. However, the ELISA technique can pro-
vide highly specific, sensitive, reliable and rapid results on
protein stability and activity and confirm which portion of
the protein released is structurally sound (39). From the
ELISA results shown in Table it can be clearly concluded that,
over the 56-day period, high levels (>90% in all cases) of active
protein were continually released. This is a notable finding as
current PLGA based implants commonly result in degrada-
tion of the encapsulated protein molecules during the release
lifetime. A major advantage of this PEGDA based release
system is its ability to prevent inactivation of protein over the
current release period. This benefit can be attributived to the
hydrophilic nature of PEGDA, unlike PLGA, which can com-
monly cause not only a drop in pH upon degradation (40),
resulting in protein denaturation, but also hydrophobic inter-
actions between the polymer and protein molecule hindering
drug release (41).
Swelling results indicate that higherMWPEGDA implants
result in increased system swelling (15). This likely occurs due
to high crosslink density within the system when lower MW
PEGDA is used, resulting in less space within the network for
water ingression and thus swelling potential (42). The addition
of pore forming agent on swelling percentage is minimal with
both low and higher MW PEGDA systems. As the results
stated, no pore-forming agent loaded in PEGDA 700 or
PEGDA 250 implants demonstrated a significant difference
in swelling when compared to the control formulation (with
the exception of gelatin (C9) loaded PEGDA 700 implants).
This indicates that polymer MW is the key factor influencing
swelling. It is likely that the PEGDA 700 system has reached
its maximum swelling capacity and once this is reached the
introduction of pore formers does not induce an increase in
swelling as the system is saturated. In contrast the PEGDA
250 system is so tightly crosslinked that water cannot access
the system and consequently pore forming loading has mini-
mal effect on swelling (36).
From the implant swelling data, network parameters were
utilised to assess crosslink density (Ve), polymer-water interac-
tion parameter (χ), average molecular weight between
crosslinks (Mc), and mesh size (ε). Network parameters were
employed to characterise the complex system structure and
evaluate the degree of crosslinking and interaction occurring
within the implant formulations (32). As demonstrated by the
network parameters, a decrease in polymer chain length re-
sults in an increase in crosslink density (Ve) within the system.
Indicating that PEGDA 250 implants are more densely
crosslinked than their PEGDA 700 counterparts and account-
ing for the significant differences observed with TA release
from the varying MW systems.
Higher χ values for PEGDA 250 implants indicating more
polymer-polymer interaction within these systems (32) and
thus less polymer-water interactions i.e. increasing crosslinking
densities decreases the interaction between the polymeric sys-
tem and water. This is demonstrated by the swelling data,
which shows a drastic reduction in swelling from PEGDA
250 systems when compared with those composed of
PEGDA 700. As the results highlighted, formulations com-
posed of higherMWPEGDA resulted in higherMc andmesh
size values, which is due to lower crosslink densities, Ve. By
decreasing PEGDAMW, the shorter chained monomer mol-
ecules are capable of crosslinking tighter, resulting in the in-
crease in crosslinking densities of these hydrogels.
Consequently, decreasing PEGDA MW resulted in more rig-
id network structures, due to an increased number of
Top sectional view          Cross-sectional view
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b
c
d
Fig. 8 SEM images showing non-drug loaded implants after 24 h in PBS (a)
C1, (b) C2, (c) C7, (d) C8.
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crosslinks within the network, which also produced less water
ingression into the system and thus the decrease in swelling
potential of the lower MW PEGDA systems.
As small alterations in photocrosslinked PEGDA formula-
tion composition have the ability to majorly affect the systems
network parameters it is important to ensure that implant
mechanical strength is preserved throughout these changes.
PEGDA has been shown to be extremely responsive to me-
chanical modification (43), resulting in hydrogels with flexible
properties for drug delivery. Nevertheless, it’s imperative that
a b c
d e f
Fig. 9 SEM images showing mannitol loaded PEGDA 700 implants after 24 h in PBS (a) C3, (b) T3, (b) O3 andmannitol loaded PEGDA 250 implants after 24 h
in PBS, (d) C4, (e) T4, and (f) O4.
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mechanical strength remains intact to allow implant place-
ment and drug release without substantial bending or break-
ing of the implant system. Mechanical strength data indicates,
that in the dry state, the polymer structures exhibit more rigid
polymer chains, and no pores were visible within the structure
(although they may be present, but at such a small pore size
that they cannot be detected). Due to the lack of visible pores
within the implant structure until they are exposed to an aque-
ous environment, it stands to reason that all dry implants will
exhibit greater mechanical strength than wetted implants.
The addition of pore former within the implant adds to
implant structure and strength when dry, making them harder
to compress. In contrast when the implants are subjected to an
aqueous environment, for 24 h and mechanical strength is
retested, all the wetted samples are consistently weaker than
the control of no pore former (with the exception of formula-
tion C4, which still shows increased mechanical strength than
the control implant). The decrease in mechanical strength
observed in the PEGDA 700 implants, was not statistically
significant, however, all PEGDA 250 implants loaded with
pore forming agents were significantly weaker than the control
(C2) formulation (with the exception of sodium bicarbonate
(C8)). Indicating the pore forming agents produce pores with-
in the implant structure on addition to PBS, decreasing the
mechanical strength of the implants. When comparing the
effect of PEGDA MW on implant mechanical strength, all
PEGDA 250 implants are consistently significantly stronger
than their PEGDA 700 counterparts, both when dry
(p< .0001), and upon wetting (p< .0001). This is likely due
to the smaller MW monomers providing tighter crosslinkage
within the system, requiring more force to compress and
resulting in an increased mechanical strength.
SEM images support all previously discussed data, with
Fig. 8 highlighting the smooth external and internal surfaces
of control implants, containing no pore forming agent (C1 and
C2) compared to the more porous appearance of those im-
plants loaded with sodium carbonate (formulations C7 and
C8). All PEGDA 700 implants are noticeably more porous
than the lower MW PEGDA implants in the top sectional
image. Suggesting a faster rate of release, increased swelling
and lower crosslink densities should be expected from the high
MW systems.
Additionally, SEM images, as shown in Fig. 9, help support
the hypothesis of a potential interaction between the pore
forming agents mannitol and maltose and the OVA protein
molecule. Figure 9 highlights the effect of drug loading and
drug type on pore formers ability to produce pores within the
system. It is clear that the drug type has minimal visual effect
on pore formation, further indicating that the decrease in
OVA release from mannitol loaded implants is not due to
the inability of mannitol (and indeed maltose) to form pores,
but rather an interaction or crystallisation of these pore
forming agents and the protein molecule preventing release
(38). This in turn explains why mannitol loaded TA formula-
tions do not experience the same decrease in drug release that
is observed within the OVA formulations.
Biocompatibility studies were conducted using ARPE-19
cells to assess any potential toxicity issues with the formula-
tions. Specifically, there was concern that toxicity could arise
from unreacted monomer with the photocrosslinked system
(44). Cell viability results shown in Fig. 10 and Fig. 11 indicate
that both PEGDA 700 and PEGDA 250 implants were non-
toxic to cells. With regards to indirect contact testing, cell
exposure to release media collected on day 1 from PEGDA
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Fig. 12 Showing DAPI staining of ARPE-19 cells after exposure to
photocrosslinked implants of Formulation C1 and C2 by (a) indirect contact
assay (b) direct contact assay.
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250 implants resulted in the lowest percentage of cell viability,
86.21%. The ISO standard for tests for in vitro cytotoxicity
state that a cell viability reading of below 70% is considered
a cytotoxic effect (45). Thus, results signify lack of cytotoxicity
for all formulations tested. Figure 12 highlights the high por-
tion of live cells (stained blue) present post indirect and direct
contact exposure and that the ARPE-19 cells maintain the
morphology following exposure. The biocompatibility results
are promising and indicate that both the photocrosslinked
PEGDA polymer (at MW 250 and 700) and the
photoinitiator, Irgacure® 2959, at this concentration are
non-toxic to retinal epithelial cells. Photoinitiator selection,
along with the polymer used, plays a major role in the
crosslinked system that is formed. In this study we use the a
type I α-hydroxyalkylphenone (Irgacure® molecule), which is
a member of a group of photoinitiator compounds suitable for
polymerisation reactions (22). Irgacure® 2959 is an extremely
effective type I photoinitiator used in UV photocrosslinked
systems (23), and is also suitable for use in aqueous systems
or environments (23). Additionally, Irgacure® 2959 is activat-
ed by low intensity UV light at a wavelength of 365 nm (24),
which is less damaging to tissues and helps further explain its
low toxicity. When activated Irgacure® photoinitiators form
benzoyl and alkyl radicals, both radicals are reactive to initiate
photo-polymerisation but the benzoyl radical presents higher
reactivity (46). This free radical formation could have resulted
in toxicity, but this study has disproved that. In addition,
Williams et al. tested a range of α-hydroxyalkylphenones
photoinitiators, findings showed that the photoinitiator 2-hy-
droxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone
(Irgacure® 2959) exhibited minimal toxicity in mammalian
cells lines, including corneal epithelial cells lines (24), and
was well tolerated at a range of concentrations, between
0.03–0.1% w/w (24,47) supporting findings in this study.
This suggests Irgacure® 2959 is a suitable photoinitiator
choice and could be safely used in preparations intended for
ocular use.
CONCLUSION
Photocrosslinked PEGDA implants investigated in this study
can provide sustained delivery of both small and large mole-
cules. We have demonstrated that the implant system is capa-
ble of releasing bioactive protein molecules over at least a
2 month time period. Additionally, this study shows varying
PEGDAMW and/or the addition of pore forming agents can
affect drug release from the implant based system and alter its
mechanical strength and swelling properties. Thus indicating
that this delivery system has the capability to control the drug
release by varying the implant composition.
Future work will focus on exploiting PEGDA’s tuneable
nature to optimise crosslink density and thus further improve
drug release. Different approaches will be investigated for
each drug molecule, given their varied physical and chemical
properties. The primary aim is to adapt the PEGDA implant
system to provide at least 3 months release of active protein,
along with desirable mechanical and thermal properties.
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